BNP Paribas Financial Markets’s GALENA BIOPHARMA INC COM RXII Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-13,266
| Closed | -$4.64K | – | 4280 |
|
|
2016
Q3 | $4.64K | Buy |
13,266
+1,277
| +11% | +$447 | ﹤0.01% | 3399 |
|
|
2016
Q2 | $5.63K | Buy |
+11,989
| New | +$5.63K | ﹤0.01% | 3217 |
|
|
2016
Q1 | – | Sell |
-31,746
| Closed | -$46.7K | – | 3563 |
|
|
2015
Q4 | $46.7K | Sell |
31,746
-3,916
| -11% | -$5.76K | ﹤0.01% | 2853 |
|
|
2015
Q3 | $56.3K | Buy |
35,662
+22,208
| +165% | +$35.1K | ﹤0.01% | 2773 |
|
|
2015
Q2 | $22.9K | Buy |
13,454
+10,733
| +394% | +$18.2K | ﹤0.01% | 2958 |
|
|
2015
Q1 | $3.78K | Buy |
+2,721
| New | +$3.78K | ﹤0.01% | 3299 |
|
|
2014
Q4 | – | Sell |
-87,041
| Closed | -$179K | – | 4118 |
|
|
2014
Q3 | $179K | Buy |
87,041
+33,269
| +62% | +$68.5K | ﹤0.01% | 1911 |
|
|
2014
Q2 | $165K | Buy |
53,772
+53,449
| +16,548% | +$164K | ﹤0.01% | 1861 |
|
|
2014
Q1 | $791 | Sell |
323
-1,111
| -77% | -$2.72K | ﹤0.01% | 2933 |
|
|
2013
Q4 | $7.11K | Sell |
1,434
-16,223
| -92% | -$80.5K | ﹤0.01% | 2867 |
|
|
2013
Q3 | $40.3K | Sell |
17,657
-16,957
| -49% | -$38.7K | ﹤0.01% | 2533 |
|
|
2013
Q2 | $76.8K | Buy |
+34,614
| New | +$76.8K | ﹤0.01% | 2589 |
|
BNP Paribas Financial Markets's RXII Position: Q4 2016 in Review
BNP Paribas Financial Markets sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 13,266 shares — an estimated $4.64K sold.
BNP Paribas Financial Markets first reported a position in RXII in Q2 2013 and held it in 12 quarters. The position peaked at $179K in Q3 2014. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.
- BNP Paribas Financial Markets reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
- BNP Paribas Financial Markets sold 13,266 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $4.64K.
- BNP Paribas Financial Markets first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 12 quarters.
- BNP Paribas Financial Markets's GALENA BIOPHARMA INC COM position peaked at $179K in Q3 2014.
- 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.
Based on BNP Paribas Financial Markets's 13F filing for Q4 2016, filed 14 Feb 2017.